TRULANCE (plecanatide)
IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+1
SALIX/BAUSCH HE
Drug class
Irritable Bowel Syndrome Agents
Irritable bowel syndrome agents constitute a therapeutic class of gastrointestinal medications designed to manage the abdominal pain, discomfort, and altered bowel motility characteristic of irritable bowel syndrome. Read more about Irritable Bowel Syndrome Agents
50 drugs in this class 43 manufacturers
Drugs in Irritable Bowel Syndrome Agents
XIFAXAN (rifaximin)
RIFAMYCINS · DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
SALIX/BAUSCH HE
MOVANTIK (naloxegol oxalate)
OPIOID ANTAGONISTS · OPIOID-INDUCED CONSTIPATION
VALINOR/AVERITA
AMITIZA (lubiprostone)
IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
Takeda Pharmaceuticals America
XIFAXAN (rifaximin)
RIFAMYCINS · DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
SALIX PHARMACEU
ALOSETRON HCL
IRRITABLE BOWEL SYNDROME AGENTS · DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME
ROXANE/WEST-WAR
LOTRONEX (alosetron HCl)
IRRITABLE BOWEL SYNDROME AGENTS · DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME
SEBELA PHARMACE
ALOSETRON HCL
IRRITABLE BOWEL SYNDROME AGENTS · DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME
Amneal Pharmaceuticals
LINZESS (linaclotide)
IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2
Allergan
Filter & compare in the drug finder →
Opens the drug finder with Irritable Bowel Syndrome Agents preselected. Add indication or manufacturer filters there.
Irritable bowel syndrome agents constitute a therapeutic class of gastrointestinal medications designed to manage the abdominal pain, discomfort, and altered bowel motility characteristic of irritable bowel syndrome.
Rather than sharing a single mechanism of action, the class encompasses diverse pharmacologic subclasses tailored to specific disease subtypes, including chloride channel activators, guanylate cyclase-C agonists, and sodium-hydrogen exchanger inhibitors that stimulate intestinal fluid secretion to relieve constipation, as well as serotonin 5-HT3 receptor antagonists and mixed opioid receptor modulators that slow transit and reduce visceral hypersensitivity to control diarrhea.
Consequently, these agents are indicated for the management of irritable bowel syndrome with constipation (IBS-C) and irritable bowel syndrome with diarrhea (IBS-D) in adult patients.
-
fda.gov
Irritable bowel syndrome agents constitute a therapeutic class of gastrointestinal medications designed to manage the abdominal pain, discomfort, and altered bowel motility characteristic of irritable bowel syndrome
-
nih.gov
Irritable bowel syndrome agents constitute a therapeutic class of gastrointestinal medications designed to manage the abdominal pain, discomfort, and altered bowel motility characteristic of irritable bowel syndrome Rather than sharing a single mechanism of action, the class encompasses diverse pharmacologic subclasses tailored to specific disease subtypes, including chloride channel activators, guanylate cyclase-C agonists, and sodium-hydrogen exchanger inhibitors that stimulate intestinal flui...
-
nih.gov
Rather than sharing a single mechanism of action, the class encompasses diverse pharmacologic subclasses tailored to specific disease subtypes, including chloride channel activators, guanylate cyclase-C agonists, and sodium-hydrogen exchanger inhibitors that stimulate intestinal fluid secretion to relieve constipation, as well as serotonin 5-HT3 receptor antagonists and mixed opioid receptor modulators that slow transit and reduce visceral hypersensitivity to control diarrhea Consequently, these...
-
nih.gov
Rather than sharing a single mechanism of action, the class encompasses diverse pharmacologic subclasses tailored to specific disease subtypes, including chloride channel activators, guanylate cyclase-C agonists, and sodium-hydrogen exchanger inhibitors that stimulate intestinal fluid secretion to relieve constipation, as well as serotonin 5-HT3 receptor antagonists and mixed opioid receptor modulators that slow transit and reduce visceral hypersensitivity to control diarrhea Consequently, these...
-
nih.gov
Rather than sharing a single mechanism of action, the class encompasses diverse pharmacologic subclasses tailored to specific disease subtypes, including chloride channel activators, guanylate cyclase-C agonists, and sodium-hydrogen exchanger inhibitors that stimulate intestinal fluid secretion to relieve constipation, as well as serotonin 5-HT3 receptor antagonists and mixed opioid receptor modulators that slow transit and reduce visceral hypersensitivity to control diarrhea Consequently, these...
-
nih.gov
Rather than sharing a single mechanism of action, the class encompasses diverse pharmacologic subclasses tailored to specific disease subtypes, including chloride channel activators, guanylate cyclase-C agonists, and sodium-hydrogen exchanger inhibitors that stimulate intestinal fluid secretion to relieve constipation, as well as serotonin 5-HT3 receptor antagonists and mixed opioid receptor modulators that slow transit and reduce visceral hypersensitivity to control diarrhea
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.